Herantis Pharma announces approval of Clinical Trial Application (CTA) for a Phase 1 study for HER-096
Herantis Pharma Plc, Press release, 20 February 2023 at 13:00p.m. EET Herantis will initiate the Phase 1 study with the aim to demonstrate evidence of HER-096 safety and blood-brain penetration in humans. Herantis Pharma Plc ("Herantis"), a company developing disease-modifying therapies for Parkinson’s disease, is pleased to announce that the Finnish Medicines Agency, Fimea and the ethics committee have approved the Clinical Trial Application (CTA) submitted in December 2022. The Phase 1 study will be conducted in Finland. “We are excited to commence HER-096 clinical development”,